1.Commission WMH: Report of clustering pneumonia of unknown etiology in Wuhan City. Accessed March 31, 2020. Available at: http://wjw.wuhan.gov.cn/front/web/showDetail/2019123108989.
2.Chan JF, Yuan S, Kok KH, To KK, et al: A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020; 395(10223):514–523
3.Guo YR, Cao QD, Hong ZS, Tan YY, et al: The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID–19) outbreak - an update on the status. Mil Med Res 2020; 7(1):11
4.Surveillances V: The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID–19)—China, 2020. China CDC Weekly 2020; 2(8):113–122
5.Chen N, Zhou M, Dong X, Qu J, et al: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223):507–513
6.Zhou F, Yu T, Du R, Fan G, et al: Clinical course and risk factors for mortality of adult inpatients with COVID–19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229):1054–1062
7.Chen T, Wu D, Chen H, Yan W, et al: Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. Bmj 2020; 368:m1091
8.Stang A: Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European journal of epidemiology 2010; 25(9):603–605
9.Cao J, Tu WJ, Cheng W, Yu L, et al: Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease 2019 in Wuhan, China. Clin Infect Dis 2020 DOI: 10.1093/cid/ciaa243.
10.Chen T, Dai Z, Mo P, Li X, et al: Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID–19) in Wuhan, China (2019): a single-centered, retrospective study. J Gerontol A Biol Sci Med Sci 2020 DOI: 10.1093/gerona/glaa089.
11.Cheng Y, Luo R, Wang K, Zhang M, et al: Kidney disease is associated with in-hospital death of patients with COVID–19. Kidney Int 2020; 97(5):829–838
12.Deng Y, Liu W, Liu K, Fang YY, et al: Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID–19) in Wuhan, China: a retrospective study. Chin Med J (Engl) 2020 DOI: 10.1097/cm9.0000000000000824.
13.Du RH, Liang LR, Yang CQ, Wang W, et al: Predictors of Mortality for Patients with COVID–19 Pneumonia Caused by SARS-CoV–2: A Prospective Cohort Study. Eur Respir J 2020 DOI: 10.1183/13993003.00524–2020.
14.Feng Y, Ling Y, Bai T, Xie Y, et al: COVID–19 with Different Severity: A Multi-center Study of Clinical Features. Am J Respir Crit Care Med 2020 DOI: 10.1164/rccm.202002–0445OC.
15.Grasselli G, Zangrillo A, Zanella A, Antonelli M, et al: Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV–2 Admitted to ICUs of the Lombardy Region, Italy. Jama 2020 DOI: 10.1001/jama.2020.5394.
16.Hu H, Yao N, Qiu Y: Comparing rapid scoring systems in mortality prediction of critical ill patients with novel coronavirus disease. Acad Emerg Med 2020 DOI: 10.1111/acem.13992.
17.KCDC: Cases of COVID–19 in Korea (as of 00 on 4.30.). Accessed April 30, 2020 Available at: http://ncov.mohw.go.kr/bdBoardList_Real.do?brdId = 1&brdGubun = 11&ncvContSeq = &contSeq = &board_id = &gubun = .
18.Li J, Wang X, Chen J, Zhang H, et al: Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID–19) Infection in Wuhan, China. JAMA Cardiol 2020 DOI: 10.1001/jamacardio.2020.1624.
19.Li X, Xu S, Yu M, Wang K, et al: Risk factors for severity and mortality in adult COVID–19 inpatients in Wuhan. J Allergy Clin Immunol 2020 DOI: 10.1016/j.jaci.2020.04.006.
20.Liang WH, Guan WJ, Li CC, Li YM, et al: Clinical characteristics and outcomes of hospitalised patients with COVID–19 treated in Hubei (epicenter) and outside Hubei (non-epicenter): A Nationwide Analysis of China. Eur Respir J 2020 DOI: 10.1183/13993003.00562–2020.
21.Richardson S, Hirsch JS, Narasimhan M, Crawford JM, et al: Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID–19 in the New York City Area. Jama 2020 DOI: 10.1001/jama.2020.6775.
22.Ruan Q, Yang K, Wang W, Jiang L, et al: Correction to: Clinical predictors of mortality due to COVID–19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020 DOI: 10.1007/s00134–020–06028-z.
23.Shi S, Qin M, Shen B, Cai Y, et al: Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID–19 in Wuhan, China. JAMA Cardiol 2020 DOI: 10.1001/jamacardio.2020.0950.
24.SiVies: Informe COVID–19 nº 27. 30 de abril de 2020. Accessed April 30, 2020. Available at: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Paginas/InformesCOVID–19.aspx.
25.Wu C, Chen X, Cai Y, Xia J, et al: Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020 DOI: 10.1001/jamainternmed.2020.0994.
26.Xu B, Fan CY, Wang AL, Zou YL, et al: Suppressed T cell-mediated immunity in patients with COVID–19: A clinical retrospective study in Wuhan, China. J Infect 2020 DOI: 10.1016/j.jinf.2020.04.012.
27.Yang X, Yu Y, Xu J, Shu H, et al: Clinical course and outcomes of critically ill patients with SARS-CoV–2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020 DOI: 10.1016/S2213–2600(20)30079–5.
28.Yuan M, Yin W, Tao Z, Tan W, et al: Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China. PLoS One 2020; 15(3):e0230548
29.Zhang J, Wang X, Jia X, Li J, et al: Risk factors for disease severity, unimprovement, and mortality in COVID–19 patients in Wuhan, China. Clin Microbiol Infect 2020 DOI: 10.1016/j.cmi.2020.04.012.
30.Wang B, Li R, Lu Z, Huang Y: Does comorbidity increase the risk of patients with COVID–19: evidence from meta-analysis. Aging (Albany NY) 2020; 12 DOI: 10.18632/aging.103000.
31.Li LQ, Huang T, Wang YQ, Wang ZP, et al: COVID–19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol 2020 DOI: 10.1002/jmv.25757.
32.Zheng Z, Peng F, Xu B, Zhao J, et al: Risk factors of critical & mortal COVID–19 cases: A systematic literature review and meta-analysis. J Infect 2020 DOI: 10.1016/j.jinf.2020.04.021.
33.Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, Villamizar-Pena R, et al: Clinical, laboratory and imaging features of COVID–19: A systematic review and meta-analysis. Travel Med Infect Dis 2020:101623
34.Cao Y, Liu X, Xiong L, Cai K: Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV–2: A systematic review and meta-analysis. J Med Virol 2020 DOI: 10.1002/jmv.25822.
35.Zhu H, Rhee JW, Cheng P, Waliany S, et al: Cardiovascular Complications in Patients with COVID–19: Consequences of Viral Toxicities and Host Immune Response. Curr Cardiol Rep 2020; 22(5):32
36.Nalivaiko E: Tachycardia during fever: is it neural or humoral? Am J Physiol Regul Integr Comp Physiol 2006; 290(6):R1750; author reply R1751
37.Ren W, Pan H, Wang P, Lan L, et al: Clinical analysis of pulmonary infection in hemodialysis patients. Exp Ther Med 2014; 7(6):1713–1717
38.Wang D, Hu B, Hu C, Zhu F, et al: Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Jama 2020; 323(11):1061–1069
39.Wu Z, McGoogan JM: Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID–19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. Jama 2020 DOI: 10.1001/jama.2020.2648.
40.Smeeth L, Thomas SL, Hall AJ, Hubbard R, et al: Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004; 351(25):2611–2618
41.Badawi A, Ryoo SG: Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis 2016; 49:129–133
42.Hu C, Jia W: Diabetes in China: Epidemiology and Genetic Risk Factors and Their Clinical Utility in Personalized Medication. Diabetes 2018; 67(1):3–11
43.Su Y, Ju MJ, Ma JF, Tu GW, et al: Lactate dehydrogenase as a prognostic marker of renal transplant recipients with severe community-acquired pneumonia: a 10-year retrospective study. Ann Transl Med 2019; 7(22):660
44.Apple FS: Tissue specificity of cardiac troponin I, cardiac troponin T and creatine kinase-MB. Clin Chim Acta 1999; 284(2):151–159
45.Lelubre C, Anselin S, Zouaoui Boudjeltia K, Biston P, et al: Interpretation of C-reactive protein concentrations in critically ill patients. Biomed Res Int 2013; 2013:124021
46.Wannamethee SG, Whincup PH, Lennon L, Papacosta O, et al: Associations between fibrin D-dimer, markers of inflammation, incident self-reported mobility limitation, and all-cause mortality in older men. J Am Geriatr Soc 2014; 62(12):2357–2362
47.Castelli GP, Pognani C, Cita M, Stuani A, et al: Procalcitonin, C-reactive protein, white blood cells and SOFA score in ICU: diagnosis and monitoring of sepsis. Minerva Anestesiol 2006; 72(1–2):69–80
48.Ruan QR, Yang K, Wang WX, Jiang LY, et al: Clinical predictors of mortality due to COVID–19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Medicine DOI: 10.1007/s00134–020–05991-x.
49.Li K, Wu J, Wu F, Guo D, et al: The Clinical and Chest CT Features Associated with Severe and Critical COVID–19 Pneumonia. Invest Radiol 2020 DOI: 10.1097/RLI.0000000000000672.
50.Huang C, Wang Y, Li X, Ren L, et al: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223):497–506
51.Boonnak K, Vogel L, Feldmann F, Feldmann H, et al: Lymphopenia associated with highly virulent H5N1 virus infection due to plasmacytoid dendritic cell-mediated apoptosis of T cells. J Immunol 2014; 192(12):5906–5912
52.Tan L, Wang Q, Zhang D, Ding J, et al: Lymphopenia predicts disease severity of COVID–19: a descriptive and predictive study. Signal Transduct Target Ther 2020; 5:33
53.Guan CS, Lv ZB, Yan S, Du YN, et al: Imaging Features of Coronavirus disease 2019 (COVID–19): Evaluation on Thin-Section CT. Acad Radiol 2020; 27(5):609–613 DOI: 10.1016/j.acra.2020.03.002.
54.Bansal M: Cardiovascular disease and COVID–19. Diabetes Metab Syndr 2020; 14(3):247–250
55.Bonow RO, Fonarow GC, O’Gara PT, Yancy CW: Association of Coronavirus Disease 2019 (COVID–19) With Myocardial Injury and Mortality. JAMA Cardiol 2020 DOI: 10.1001/jamacardio.2020.1105.
56.Guo T, Fan Y, Chen M, Wu X, et al: Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID–19). JAMA Cardiol 2020 DOI: 10.1001/jamacardio.2020.1017.
57.Alhogbani T: Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus. Ann Saudi Med 2016; 36(1):78–80
58.Zhang H, Penninger JM, Li Y, Zhong N, et al: Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV–2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020; 46(4):586–590
59.Akcay A, Nguyen Q, Edelstein CL: Mediators of inflammation in acute kidney injury. Mediators Inflamm 2009; 2009:137072